4 Apr, 2024
\n \n \n \nIn the first week of April each year, the global community comes together to celebrate health workers, the backbone of the health industry and society.
\n \n\n \n \n26 Mar, 2024
\n \n \n \nResearchers at the Nuffield Department of Medicine, the Francis Crick Institute and University College London have been granted \u00a31.7 million of funding from Cancer Research UK and the CRIS Cancer Foundation to develop a lung cancer vaccine. The group includes Professor Tim Elliott, Kidani Professor of Immuno-oncology at NDM.
\n \n\n \n \n25 Mar, 2024
\n \n \n \nThe Centre for Medicines Discovery (CMD) at NDM, has recently partnered with Ono Pharmaceutical Co (Ono) to validate and develop novel targets in a bid to discover innovative medicines.
\n \n\n \n \n21 Mar, 2024
\n \n \n \nThe Pandemic Sciences Institute at NDM, in collaboration with the global coalition of health research funders GloPID-R and UKCDR, has launched a new research programme including an interactive platform to track and analyse over $7 billion in global pandemic research funding.
\n \n\n \n \n15 Mar, 2024
\n \n \n \nThe Oxford Experimental Medicine Clinical Research Facility hosted by the Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences has expanded its capability to undertake research bronchoscopies. The facility welcomed its first volunteers as part of the Oxford Airways Study to help understand the causes of asthma.
\n \n\n \n \n11 Mar, 2024
\n \n \n \nResearchers from the Oxford BRC and other collaborating organisations have received funding to set up a UK registry for children and adults who are at risk of type 1 diabetes and have tested positive for diabetes autoantibodies.
\n \n\n \n \n8 Mar, 2024
\n \n \n \nDr Suwarti (Atie) began her journey with OUCRU Indonesia in 2018 as an awardee of the OUCRU Young Scientist Fellowship programme, when she embarked on a research journey into leptospirosis, a neglected tropical disease. Her curiosity and commitment to improving health outcomes have seen her research interests expand to the molecular diagnostic of Tuberculosis, Covid-19, and HIV.
\n \n\n \n \n7 Mar, 2024
\n \n \n \nA global, interdisciplinary team of researchers, including the Centre for Medicines Discovery\u2019s Professor Frank von Delft, has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle the solid tumours in children challenge. The Cancer Grand Challenges PROTECT team is led by Professor Stefan Pfister of the Hopp Children's Cancer Center in Heidelberg.
\n \n\n \n \n1 Mar, 2024
\n \n \n \nOxford University Clinical Research Unit\u2019s host and partner in Ho Chi Minh City, the Hospital for Tropical Diseases, was recently honoured with the Vietnam 2023 Medical Achievement Award at an event hosted by Voice of Ho Chi Minh City (VoH).
\n \n\n \n \n28 Feb, 2024
\n \n \n \nLed by Benjamin Tsofa and Jacob McKnight, at the KEMRI-Wellcome Trust Research Programme, a new project called \"A Novel Extreme Weather Risk Insurance System for Kenya (NEWRISK)\u201d will focus on using the latest methods to provide focused data on extreme weather, population vulnerability, and health system capacity readiness across various climatic zones in Kenya.
\n \n\n \n \n8 Feb, 2024
\n \n \n \nThe AI-driven Structure-enabled Antiviral Platform (ASAP) has won an Exemplary Achievement Award from the Federation of American Societies for Experimental Biology (FASEB) and the National Institutes of Health (NIH). The prize recognises data practices in biological and biomedical research labs during the active phase of research.
\n \n\n \n \n6 Feb, 2024
\n \n \n \nThe University of Oxford has entered into an agreement with three Brazilian universities, to contribute to the delivery of an undergraduate course in \u2018Translational Science\u2019, starting in 2024. The course will teach the full journey of a product \u2018from bench to bedside\u2019 as part of any science degree to prepare the next generation of researchers for the translation of their laboratory discoveries into patient care and prevention.
\n \n\n \n \n29 Jan, 2024
\n \n \n \nResearchers at the Jenner Institute, the Oxford Vaccine Group and the Pandemic Sciences Institute hosted the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.
\n \n\n \n \n17 Jan, 2024
\n \n \n \nResearchers from a wide range of disciplines have been appointed to be the next cohort of NIHR Oxford Senior Research Fellows - seven mid-career researchers identified as having the potential to become future translational research leaders. The cohort includes Dr Matthias Friedrich from the Translational Gastroenterology Unit in NDM\u2019s Experimental Medicine Division.
\n \n\n \n \n16 Jan, 2024
\n \n \n \nThe Jenner Institute at NDM is conducting a new study using the Bacille Calmette-Gu\u00e9rin (BCG) vaccine, the only vaccine currently licensed against tuberculosis. People who have received the BCG vaccine previously will be given it again to compare whether giving it by inhalation is better at protecting people against tuberculosis than giving it through the skin.
\n \n\n \n \n11 Jan, 2024
\n \n \n \nThe first clinical trial participants received doses of the ChAdOx1 NipahB vaccine this week at the University of Oxford. This is the first-in-human trial of the vaccine, being developed by researchers at the Pandemic Sciences Institute.
\n \n\n \n \n4 Jan, 2024
\n \n \n \nThe R21/Matrix-M malaria vaccine developed by The Jenner Institute and the Serum Institute of India, is one step closer to mass rollout, after officially receiving WHO prequalification status, making it eligible for procurement by United Nations agencies.
\n \n\n \n \n3 Jan, 2024
\n \n \n \nA partnership between CEPI, Barinthus Biotherapeutics and the University of Oxford aims to fast-track the development of a potential vaccine for the prevention of Middle East Respiratory Syndrome (MERS).
\n \n\n \n \n13 Dec, 2023
\n \n \n \nAn international network of researchers, led by NDM\u2019s Professor Helen McShane and Professor Samantha Sampson from Stellenbosch University, has recently been awarded a new UK Medical Research Council (MRC) grant to continue the network activities until 2027.
\n \n\n \n \n11 Dec, 2023
\n \n \n \nThe first patient in Oxfordshire has been treated in an mRNA cancer vaccine trial at Oxford University Hospitals NHS Foundation trust (OUH). The trial, led locally by Dr Ketan Shah, consultant clinical oncologist at OUH, marks a significant milestone in the national cancer vaccine advance.
\n \n\n \n \n